US 11,653,689 B2
Probiotic Bifidobacterium breve strain and compositions comprising said strain
Brynjulf Mortensen, Hoersholm (DK); Anders Damholt, Hoersholm (DK); Anja Wellejus, Hoersholm (DK); Vibeke Westphal Stennicke, Hoersholm (DK); and Johan E. T. Van Hycklama Vlieg, Hoersholm (DK)
Assigned to Chr. Hansen A/S, Hoersholm (DK)
Appl. No. 17/51,653
Filed by Chr. Hansen A/S, Hoersholm (DK)
PCT Filed May 1, 2019, PCT No. PCT/EP2019/061161
§ 371(c)(1), (2) Date Oct. 29, 2020,
PCT Pub. No. WO2019/211341, PCT Pub. Date Nov. 7, 2019.
Claims priority of application No. 8170250 (EP), filed on May 1, 2018.
Prior Publication US 2021/0153535 A1, May 27, 2021
Int. Cl. A23L 33/135 (2016.01); A61P 1/00 (2006.01); A61K 35/745 (2015.01); A61K 45/06 (2006.01)
CPC A23L 33/135 (2016.08) [A61K 35/745 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01)] 19 Claims
OG exemplary drawing
 
1. A method of supporting defense against intestinal tissue damage in a subject in need thereof, comprising orally administering to the subject a therapeutically effective amount of bacteria of Bifidobacterium breve strain DSM 32356 deposited at DSMZ-Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) under accession number DSM 32356.